Search
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
Phospho-p130Cas (Tyr249) Polyclonal Antibody
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
图: 1 / 1
Phospho-p130Cas (Tyr249) Antibody (PA5-38378) in WB
Western blot analysis of Phospho-p130 Cas/BCAR1 pTyr249 in extracts from HepG2 cells treated with EGF (200 ng/mL, 30 mins) and A549 cells treated with PMA (125 ng/mL, 30 min) using a Phospho-p130 Cas/BCAR1 pTyr249 polyclonal antibody (Product # PA5-38378).
产品信息
PA5-38378
产品规格
宿主/亚型
Rabbit
/ IgG
分类
Polyclonal
类型
Antibody
抗原
A synthetic phosphopeptide derived from human p130 Cas around the phosphorylation site of Tyr249 (D-I-YP-D-V)
偶联物
形式
Liquid
浓度
1 mg/mL
保存条件
-20°C
运输条件
Wet ice
RRID
靶标信息
The p130Cas (Cas for Crk-associated substrate) is a common cellular target of phosphorylation signal via v-Crk and v-Src oncoproteins. p130Cas has a unique structure that contains a Src homology (SH)-3 domain followed by multiple YXXP motifs and a proline-rich regionp130Cas is implicated in a variety of biological processes including cell adhesion, cell migration, growth factor stimulation, cytokine receptor engagement and bacterial infection. Physiological functions of p130Cas include cardiovascular development, actin filament assembly and Src-induced cell transformation.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
